Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577915 | 0.85 | RAB9A (0.46) | RAB9ACYP1A2CYP2A6NCF1NQO1 | |
| SCHEMBL577454 | 0.81 | PDE3B (0.40) | ALDH1A1KMT2AKDM4ELMNAPOLB | |
| SCHEMBL3490092 | 0.76 | ALDH1A1 (0.42) | RAB9ACYP1A2ALDH1A1NPC1KDM4E | |
| SCHEMBL2356812 | 0.75 | CYP1A2 (0.42) | CYP1A2CYP2A6ALDH1A1MEN1KMT2A | |
| SCHEMBL11723042 | 0.73 | CYP2A6 (0.52) | RAB9ACYP1A2CYP2A6NCF1NQO1 | |
| SCHEMBL206447 | 0.71 | BACE1 (0.38) | RAB9ACYP1A2CYP2A6ALDH1A1MEN1 | |
| SCHEMBL206485 | 0.71 | BACE1 (0.38) | CYP1A2CYP2A6NPC1KDM4ETRPA1 | |
| SCHEMBL15512056 | 0.70 | ALDH1A1 (0.35) | RAB9ACYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL443070 | 0.70 | CYP1A2 (0.79) | RAB9ACYP1A2CYP2A6NCF1NQO1 | |
| SCHEMBL29447161 | 0.70 | CYP1A2 (0.79) | RAB9ACYP1A2CYP2A6NCF1NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-10 | — | — | US | claimed |
| US-7718769-B2 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-7273851-B2 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| US-20070161575-A1 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | claimed |
| WO-2004113365-A9 | HEPATITIS C SERINE PROTEASE TRI-PEPTIDE INHIBITORS | — | 2006-03-23 | — | — | WO | claimed |
| US-20050261200-A1 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | claimed |
| WO-2004113365-A2 | HEPATITIS C SERINE PROTEASE TRI-PEPTIDE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040180815-A1 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | NAKAJIMA SUANNE (US) | 2004-09-16 | — | — | US | claimed |
| US-9284307-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8377962-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2461811-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2417134-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-7273851-B2 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070161575-A1 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2004113365-A9 | HEPATITIS C SERINE PROTEASE TRI-PEPTIDE INHIBITORS | — | 2006-03-23 | — | — | WO | disclosed |
| US-20050261200-A1 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2004113365-A2 | HEPATITIS C SERINE PROTEASE TRI-PEPTIDE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040180815-A1 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | NAKAJIMA SUANNE (US) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261200-A1 | Tri-peptide hepatitis C serine protease inhibitors | PRSS1, VIP, HPN | RAB9A 3149/4885CYP1A2 1652/4885CYP2A6 1129/4885 |
| US-20040180815-A1 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | RAB9A 2961/4885CYP1A2 361/4885CYP2A6 265/4885 |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | RAB9A 2700/4885CYP1A2 1342/4885CYP2A6 583/4885 |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | RAB9A 2215/4885CYP1A2 744/4885CYP2A6 1199/4885 |
| US-20070161575-A1 | Tri-peptide hepatitis C serine protease inhibitors | PRSS1, VIP, HPN | RAB9A 3149/4885CYP1A2 1652/4885CYP2A6 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.